JP2022523074A5 - - Google Patents
Info
- Publication number
- JP2022523074A5 JP2022523074A5 JP2021544152A JP2021544152A JP2022523074A5 JP 2022523074 A5 JP2022523074 A5 JP 2022523074A5 JP 2021544152 A JP2021544152 A JP 2021544152A JP 2021544152 A JP2021544152 A JP 2021544152A JP 2022523074 A5 JP2022523074 A5 JP 2022523074A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- composition according
- melanoma
- cell carcinoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962798406P | 2019-01-29 | 2019-01-29 | |
| US62/798,406 | 2019-01-29 | ||
| US201962881275P | 2019-07-31 | 2019-07-31 | |
| US62/881,275 | 2019-07-31 | ||
| US201962938415P | 2019-11-21 | 2019-11-21 | |
| US62/938,415 | 2019-11-21 | ||
| PCT/US2020/015723 WO2020160180A1 (en) | 2019-01-29 | 2020-01-29 | Compounds and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022523074A JP2022523074A (ja) | 2022-04-21 |
| JP2022523074A5 true JP2022523074A5 (cg-RX-API-DMAC7.html) | 2023-02-07 |
| JP7665518B2 JP7665518B2 (ja) | 2025-04-21 |
Family
ID=71841237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021544152A Active JP7665518B2 (ja) | 2019-01-29 | 2020-01-29 | 化合物及びその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230079819A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3917527B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7665518B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN113645971B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020214308A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3032327T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL285177B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020160180A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12282014B2 (en) | 2015-11-19 | 2025-04-22 | Dana-Farber Cancer Institute, Inc. | Methods of identifying compounds that interfere with ERG-driven misguidance of BAF complexes in TMPRSS2-ERG driven prostate cancers |
| EP3746124A4 (en) | 2018-01-30 | 2021-10-27 | Foghorn Therapeutics Inc. | COMPOUNDS AND THEIR USES |
| US12473334B2 (en) | 2018-10-17 | 2025-11-18 | Dana-Farber Cancer Institute, Inc. | SWI/SNF family chromatin remodeling complexes and uses thereof |
| US12384776B2 (en) | 2019-01-29 | 2025-08-12 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| US12509453B2 (en) | 2019-01-29 | 2025-12-30 | Foghorn Therapeutics Inc. | BRM/BRG1 inhibitors and uses thereof |
| EP3917517A4 (en) | 2019-01-29 | 2023-01-25 | Foghorn Therapeutics Inc. | CONNECTIONS AND USES THEREOF |
| WO2021155262A1 (en) * | 2020-01-29 | 2021-08-05 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2021155264A1 (en) | 2020-01-29 | 2021-08-05 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| BR112022015109A2 (pt) * | 2020-01-29 | 2022-11-08 | Foghorn Therapeutics Inc | Compostos e usos dos mesmos |
| WO2021236080A1 (en) * | 2020-05-20 | 2021-11-25 | Foghorn Therapeutics Inc. | Methods of treating cancers |
| US12383555B2 (en) | 2020-05-20 | 2025-08-12 | Foghorn Therapeutics Inc. | Methods of treating cancers |
| US20240132485A1 (en) * | 2020-10-16 | 2024-04-25 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof |
| US12606553B2 (en) | 2021-03-09 | 2026-04-21 | Foghorn Therapeutics Inc. | Crystalline forms, compositions containing same, and methods of their use |
| WO2022198043A1 (en) * | 2021-03-19 | 2022-09-22 | Foghorn Therapeutics Inc. | Therapeutic regimens of an inhibitor of the enzymatic activity of brg1 and brm |
| US20250339441A1 (en) * | 2022-04-08 | 2025-11-06 | Foghorn Therapeutics Inc. | Methods of treating cancer |
| AU2023278401A1 (en) * | 2022-06-02 | 2025-01-23 | Shanghai Shijiang Biotechnology Co., Ltd | Phosphorus compound and use thereof |
| CN119768400A (zh) * | 2022-11-11 | 2025-04-04 | 苏州信诺维医药科技股份有限公司 | 一种稠环化合物、其用途及含其的药物组合物 |
| WO2025082531A1 (en) * | 2023-10-20 | 2025-04-24 | Suzhou Zanrong Pharma Limited | Compounds and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005261487A1 (en) | 2004-07-12 | 2006-01-19 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Amide derivatives as inhibitors of histone deacetylase |
| EP2349484A2 (en) | 2008-07-15 | 2011-08-03 | Novartis AG | Heteroaryl derivatives as dgat1 inhibitors |
| US9656959B2 (en) | 2010-12-22 | 2017-05-23 | Purdue Pharma L.P. | Substituted pyridines as sodium channel blockers |
| MX2016012007A (es) * | 2014-03-18 | 2016-12-05 | Hoffmann La Roche | Compuestos de oxepan-2-il-pirazol-4-il-heterociclil-carboxamida y metodos de uso. |
| MA41598A (fr) * | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
| WO2018187614A1 (en) * | 2017-04-05 | 2018-10-11 | Foghorn Therapeutics | Compounds and uses thereof |
| WO2018213422A1 (en) * | 2017-05-17 | 2018-11-22 | Foghorn Therapeutics | Compounds and uses thereof |
| EP3746124A4 (en) | 2018-01-30 | 2021-10-27 | Foghorn Therapeutics Inc. | COMPOUNDS AND THEIR USES |
| EP3883580A4 (en) | 2018-11-21 | 2023-01-04 | Foghorn Therapeutics Inc. | Methods of treating cancers |
| MX2021006421A (es) | 2018-12-19 | 2021-08-16 | Leo Pharma As | Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17). |
| EA202192101A1 (ru) * | 2019-11-21 | 2021-12-09 | Фогхорн Терапьютикс Инк. | Соединения и их применение |
| IL295176A (en) * | 2020-01-29 | 2022-09-01 | Foghorn Therapeutics Inc | compounds and their uses |
-
2020
- 2020-01-29 AU AU2020214308A patent/AU2020214308A1/en not_active Abandoned
- 2020-01-29 WO PCT/US2020/015723 patent/WO2020160180A1/en not_active Ceased
- 2020-01-29 CN CN202080025628.0A patent/CN113645971B/zh active Active
- 2020-01-29 IL IL285177A patent/IL285177B2/en unknown
- 2020-01-29 EP EP20749261.2A patent/EP3917527B1/en active Active
- 2020-01-29 US US17/425,140 patent/US20230079819A1/en active Pending
- 2020-01-29 JP JP2021544152A patent/JP7665518B2/ja active Active
- 2020-01-29 ES ES20749261T patent/ES3032327T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Petroni et al. | Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment | |
| JP2024529976A5 (cg-RX-API-DMAC7.html) | ||
| JP2023512038A5 (cg-RX-API-DMAC7.html) | ||
| JP6706255B2 (ja) | 放射線、酸化セリウムナノ粒子、及び化学療法剤の併用によるがんの治療 | |
| JP2020158507A6 (ja) | 放射線、酸化セリウムナノ粒子、及び化学療法剤の併用によるがんの治療 | |
| JP2011144190A (ja) | 抗癌剤の効果増強剤 | |
| CN117919235A (zh) | 一种萘酰胺化合物治疗kras突变相关疾病的用途 | |
| RU2020114632A (ru) | Терапевтические способы, относящиеся к ингибиторам hsp90 | |
| JP2023512039A5 (cg-RX-API-DMAC7.html) | ||
| Kelly et al. | Chemotherapy in metastatic colorectal cancer | |
| Ke-Chun et al. | The role of SPDEF in cancer: promoter or suppressor. | |
| Malaponte et al. | Detection of BRAF gene mutation in primary choroidal melanoma tissue | |
| CN108434455A (zh) | Mthfd2特异性抑制剂在防治结直肠癌方面的应用 | |
| US11389536B2 (en) | Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent | |
| ES2239928T3 (es) | Metodo para reducir el dolor utilizando virus oncoliticos. | |
| CN112566628A (zh) | 预防和治疗癌症的药物组合物,包括棉酚、苯乙双胍和抗癌剂 | |
| Vieito et al. | 614MO Type II RAF inhibitor tovorafenib in recurrent/refractory (R/R) melanoma or other solid tumors with RAF fusions and/or RAF1 amplification | |
| CN115429883A (zh) | 用于联合治疗的抗肿瘤药物组合物 | |
| ES3030540T3 (en) | Treatment of breast cancer using combination therapies comprising gdc-9545 and gdc-0077 | |
| ES2389809T3 (es) | Terapias anticancerosas | |
| Irusta | Roads to the strategic targeting of ovarian cancer treatment | |
| IL307965A (en) | compounds and their uses | |
| EP4725489A2 (en) | Treatment of canine cancers | |
| CN115397422A (zh) | 包含利匹韦林的组合物和其用于治疗肿瘤或癌症的用途 | |
| JP2026516286A (ja) | マイクロペプチドmiacの使用 |